Meaning 

---

The Annual Global Discovery to Development Innovation Forum (GDDIF) is the leading pharmaceutical Research & Development summit for pharma decision makers, scientific leaders, and solutions experts. 
​
Taking a truly integrated approach to drug discovery, the 11th annual GDDIF edition remains dedicated to scientific insights, technology innovation & strategy across areas such as Medicinal Chemistry, Screening Technologies, ADME, DMPK, Open Innovation, Informatics, Discovery and Development, Artificial Intelligence, Oncology, etc.

Audience

---

Join up to 150 Decision Makers and attend the Exclusive GDDIF Leaders Summit.
Delegate job titles include:
​

• SVP R&D 
• Heads of R&D

• Medicinal Chemistry
• Heads of ADME & DMPK
• Heads of Discovery
• Principal Scientists
• Head of External Collaborations
• Heads of Toxicology
• Lab Managers | Informatics
• Heads of Pre-Clinical
• Personalised Medicine

Speakers

---

Jean Philippe Stephan - Servier

Janine Arts - Janssen

Chris Gibson - Recursion Pharma

Jorrit Hornberg - AstraZeneca

Ken Rhodes - Yumanity Therapeutics

Phil Kym - Abbvie

---

Themes

---

• Innovation within Screening, Enabling Technologies and Collaborative Partnerships
• ​CRISPR-Cas and iPSC technologies for drug discovery
• How PBPK modelling has evolved in the last decade
• PK-PD strategies implemented in early drug discovery
• How physical properties influence ADME-Tox compound progression
• The use of in-house ADME prediction tools in design
• Sequencing
• Genomics and Omics
• Understanding how to use in vitro data
• Single Cell Analysis
• Small Molecule Medicinal Chemistry: Strategies and Technologies​
• Data Analysis, Generation and Detection
• Instruments and R&D Tools
• Open-Access Collaboration in Accelerating Early Stage Drug Discovery
• How to Attract Potential Licensing Partners in Early Drug Discovery
• soloMER™ Biologics: Next-Generation Therapeutics for the Site-Specific Treatment of Inflammatory Disease
• Overcoming limitations of antibodies using engineered Affimer binding proteins
• Precision Medicine

Stream Talks

---

• Strategies for Developing 3D Cell Culture Assays
• Screening Natural Product-Based Compounds for Efficient Drug Discovery
• Insight into The New Era of Structure-Based Drug Design GPCRs
• Integrated Innovation in medicinal chemistry: what are the new technologies?

• Innovation in Medicinal Chemistry: what are the new technologies?

• Culture Assays for Use in Drug Discovery 

• Target Deconvolution Strategies in Novel Natural Compounds, Phenotypic Screening, Combined Screening 

• Evolution of Advance Natural Compounds and Potent Innovation in ADC’s 

• Sourcing and Designing More Physiologically
• The role of Open Innovation for Therapeutic Medicines

• The latest in big R&D data solutions Novel therapies in companion diagnostics 

• Relevant Cellular Assays for Implementation in HTS Programmes 

• Overcoming Patient Variability | App of Genome Editing 

• Image Analysis and Data Collection, Literature Storage and Interpretation 

• Open-Access Collaboration in Accelerating Early Stage Drug Discovery ​

Sponsor Spotlight

---

---

Media Partners

---

---

Event Partners

---

10th annual GDDIF

Client Testimonials 

Join the Conversation

---

Niclas Nilsson - Head of Open Innovation in Research

Olaf Ritzeler - Director of scouting external opportunities in Europe

Craig Johnstone - Global Head, Integrated Drug Discovery

---

In addition to the excellent networking opportunities, and inspirational speakers, this year GDDIF was a great motivational event.  We were inspired to take a step back and acknowledge the positives, and negatives, of open innovation.  This is a very exciting time as technology can and is being used more and more in the world of clinical trials and mobile applications are now recognised as medical devices.  Following a unique opportunity to interact with extraordinary leaders from around the globe, I left feeling excited as we open a new chapter of opportunities using technology in areas we have yet to dream of.  Use of the technology will enable us to be more focussed and productive so we can deliver more for less cost.
- ​ESMS Global Ltd

---

​Thank you very much for giving me the opportunity to experience an exciting GDDIF. The fruitful interactions with technology experts, company executives and pharma researchers at the GDDIF already triggered follow up activities.
- Novartis Institutes for BioMedical Research

---

Tweets by DrugDiscoveryIX

---